NCT01803035View on ClinicalTrials.gov

A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2014

Conditions
Non-bullous Impetigo
Interventions
DRUG

LTX-109 1 %

DRUG

LTX-109 2 %

DRUG

Placebo gel

Trial Locations (2)

Unknown

Dr. Robert Reid Cabral Children Hospital, Santo Domingo

Institute of Dermatology and and Skin Surgery Dr. Hubert Bogaert Diaz, Santo Domingo

Sponsors

Lead Sponsor

Lytix Biopharma AS
All Listed Sponsors
lead

Lytix Biopharma AS

INDUSTRY

NCT01803035 - A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo | Biotech Hunter | Biotech Hunter